If your patients are considering hormonal treatment they can also register to receive materials that explain in detail the risk for breast cancer recurrence and how hormonal treatment works. This information will help your patients during your discussions about treatment options.
The In Your Corner™ patient support program from AstraZeneca Pharmaceuticals LP was created with the help of oncology health care professionals and women who have had breast cancer.
When your patients enroll in the program, they will receive a series of mailings that will help them adjust to the period following initial cancer treatment; stay connected with a supportive community through monthly mailings; and receive guidance along their path from learning about their disease to focusing on everyday wellness.
If your patients are considering hormonal treatment they can also register to receive materials that explain in detail the risk for breast cancer recurrence and how hormonal treatment works. This information will help your patients during your discussions about treatment options. In addition, you can register for the In Your Corner™ patient support program, so you'll know all about the resources your patients will receive. For more information, you can click the link below.
In Your Corner™ patient support program registration
Finally, you can call the AstraZeneca Cancer Support Network 1-866-99-AZCSN (1-866-992-9276) if you have additional questions about In Your Corner, or questions on reimbursement issues, the AstraZeneca Foundation Patient Assistance Program, or Visions of Hope™ - a traveling, interactive, educational exhibit that appears at various Susan G. Komen Race for the Cure® events. The exhibit provides visitors, including breast cancer survivors and their families, with information related to breast cancer, detection, and treatment options.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More